Top stories in gastroenterology — Understanding abdominal pain in IBS, JAK inhibitor induces endoscopic remission in Crohn’s
Click Here to Manage Email Alerts
One of the top stories in gastroenterology last week was a guest commentary that provided an inside look at abdominal pain in patients with irritable bowel syndrome.
Another top story was about a study published in Gastroenterology that found the JAK inhibitor Rinvoq (upadacitinib, AbbVie) helped induce endoscopic remission among patients with moderate-to-severe Crohn’s disease.
Read these and more news in gastroenterology below:
Guest commentary: It’s time to deepen our understanding of abdominal pain in IBS
Eric D. Shah, MD, MBA, director at the Gastrointestinal Motility Center at Dartmouth-Hitchcock Medical Center, discusses his recent study on abdominal pain in IBS and argues that stratifying patients could evolve past bowel habits alone. Read more.
Rinvoq induces endoscopic remission in Crohn’s
Study results show that Rinvoq, an oral selective Janus kinase 1 inhibitor, helped induce endoscopic remission in patients with moderate-to-severe Crohn’s disease. Read more.
Symptom severity, mood linked with patient satisfaction in IBS
Factors like reduced disease severity and lower depression scores were associated with better satisfaction scores among patients with IBS, according to study results. Read more.
Real-time colonoscopy system increases adenoma yield
A real-time colonoscopy quality improvement system known as ENDOANGEL helped improve adenoma detection, according to recent study results. Read more.
Quality improvement program produces better IBD outcomes
A quality improvement program that helps facilities make changes in practice structure and share best practices helped improve outcomes among patients with IBS, according to research presented at Crohn’s and Colitis Congress. Read more.